Teva Pharmaceutical Indus (TEVA, Financial) has received significant attention from Truist Securities as the firm initiates coverage with a "Buy" rating. The announcement was made on May 28, 2025, and marks a notable development for the pharmaceutical company.
Analyst Les Sulewski from Truist Securities has set a price target of $25.00 USD for TEVA. This target reflects Truist's confidence in TEVA's potential for growth, as the company seeks to solidify its standing in the pharmaceutical market. The initiation of coverage with a positive rating indicates strong future prospects as perceived by the analyst.
The price target did not have a prior adjustment since this is a newly announced rating by Truist Securities. Investors will be keen to observe how this development influences TEVA's performance in the coming months.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Teva Pharmaceutical Industries Ltd (TEVA, Financial) is $23.15 with a high estimate of $30.00 and a low estimate of $18.07. The average target implies an upside of 28.63% from the current price of $18.00. More detailed estimate data can be found on the Teva Pharmaceutical Industries Ltd (TEVA) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, Teva Pharmaceutical Industries Ltd's (TEVA, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Teva Pharmaceutical Industries Ltd (TEVA, Financial) in one year is $11.34, suggesting a downside of 37% from the current price of $18. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Teva Pharmaceutical Industries Ltd (TEVA) Summary page.
